Barclays raised the firm’s price target on Travere Therapeutics (TVTX) to $20 from $18 and keeps an Overweight rating on the shares post the Q3 report. The firm says Filspari beat despite a slow-down in new starts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Boosts Sales with FILSPARI Approval
- Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
- Travere presents data reinforcing clinical benefit of FILSPARI in IgAN
- Wells Fargo upgrades Travere Therapeutics to Overweight on further upside
- Travere Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo